Treating type 2 diabetes in children and adolescents is especially challenging. Compared with adults, youth with type 2 diabetes often experience more rapid disease progression and earlier complications, making effective treatment strategies particularly important. A new study published in the Journal of the Endocrine Society highlights the work of Dr. Castaño, who served as lead author on a newly published retrospective analysis of the real-world effectiveness of liraglutide in children and adolescents with type 2 diabetes. Liraglutide is a GLP-1 receptor agonist. The research compared outcomes among patients who consistently took liraglutide with those who were prescribed the medication but did not use it. The investigators found a strong trend toward improved HbA1c levels after 26 weeks of treatment. Patients receiving liraglutide also experienced significant reductions in total cholesterol and LDL cholesterol compared with controls, while body mass index remained stable in both groups. The findings suggest that liraglutide may provide meaningful benefits for improving glucose control and cholesterol levels in youth with type 2 diabetes in routine clinical practice. Kudos to Dr. Castaño for his important work in this area. The manuscript’s abstract is indexed on PubMed at this link.